

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934

For the Month of January 2014

001-36203
(Commission File Number)

CAN-FITE BIOPHARMA LTD.
(Exact name of Registrant as specified in its charter)

**10 Bareket Street
Kiryat Matalon, P.O. Box 7537
Petach-Tikva 4951778, Israel**
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover
Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1): _____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7): _____

On January 22, 2014, Can-Fite BioPharma Ltd. made a filing with the Israel Securities Authority and the Tel Aviv Stock Exchange regarding an extension of warrants (Series 7). An English translation of the filing is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Exhibit Index

Exhibit No.

Description

99.1	English Translation of filing made with Israel Securities Authority and Tel Aviv Stock Exchange on January 22, 2014
------	---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Can-Fite BioPharma Ltd.

Date: January 23, 2014

By: /s/ Motti Farbstein

Motti Farbstein

Chief Operating and Financial Officer

1. Summary of the Application for Compromise or Settlement:

In accordance with the application for approval of the settlement between the Company and its shareholders and the Company and the holders of warrants (Series 7) of the Company (the "**Settlement Petition**" and / or "**Settlement**"), the court has been asked to approve the proposed Settlement under which the last date to exercise warrants (Series 7) of the Company shall be extended until March 31, 2014, all as requested in the Settlement Petition.

2. Court Decision:

After studying the application and all its appendixes, as the Israeli Security Authority and the Tel Aviv Stock Exchange have stated that they do not intend to take any position with respect to the application for approval of the proposed arrangement between the Company and the holders of the Warrants (Series 7) of the Company, and as it is clear from the settlement petition for approval of the proposed arrangement that the extension of the exercise date will provide the holders of the Warrants (Series 7) of the Company a better opportunity to exercise the said Warrants (exercise which would inject money into the company), and due to the fact that the required period under the law to file an objection did not pass yet, and in order to enable the public investor to consider his position and option in exercising the said Warrants by knowing the final date of exercise of Warrants (Series 7) of the Company - I hereby extend, as an interim relief, the date of exercise the Warrants (Series 7) of the Company until February 20, 2014.
